160 related articles for article (PubMed ID: 38238555)
21. Exploration of Potential Roles of m5C-Related Regulators in Colon Adenocarcinoma Prognosis.
Huang Y; Huang C; Jiang X; Yan Y; Zhuang K; Liu F; Li P; Wen Y
Front Genet; 2022; 13():816173. PubMed ID: 35281843
[No Abstract] [Full Text] [Related]
22. Prognostic significance and immune landscape of a fatty acid metabolism-related gene signature in colon adenocarcinoma.
Liu X; Fang X; Lu L; Liu G
Front Genet; 2022; 13():996625. PubMed ID: 36568396
[No Abstract] [Full Text] [Related]
23. Circadian Clock Genes Are Correlated with Prognosis and Immune Cell Infiltration in Colon Adenocarcinoma.
He A; Huang Z; Zhang R; Lu H; Wang J; Cao J; Feng Q
Comput Math Methods Med; 2022; 2022():1709918. PubMed ID: 35116071
[TBL] [Abstract][Full Text] [Related]
24. High MICAL-L2 expression and its role in the prognosis of colon adenocarcinoma.
Yang Y; Ye F; Xia T; Wang Q; Zhang Y; Du J
BMC Cancer; 2022 May; 22(1):487. PubMed ID: 35501725
[TBL] [Abstract][Full Text] [Related]
25. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
26. A Prognostic Model Based on the Immune-related Genes in Colon Adenocarcinoma.
Sun YL; Zhang Y; Guo YC; Yang ZH; Xu YC
Int J Med Sci; 2020; 17(13):1879-1896. PubMed ID: 32788867
[No Abstract] [Full Text] [Related]
27. Metabolism-Related Prognostic Biomarkers, Purine Metabolism and Anti-Tumor Immunity in Colon Adenocarcinoma.
Liu H; Zhang Y; Zhang Q; Zhang T; Lu T
Front Biosci (Landmark Ed); 2023 Dec; 28(12):328. PubMed ID: 38179743
[TBL] [Abstract][Full Text] [Related]
28. A Novel Pyroptosis-Related Gene Signature for Predicting the Prognosis and the Associated Immune Infiltration in Colon Adenocarcinoma.
Chen Z; Han Z; Nan H; Fan J; Zhan J; Zhang Y; Zhu H; Cao Y; Shen X; Xue X; Lin K
Front Oncol; 2022; 12():904464. PubMed ID: 35912258
[TBL] [Abstract][Full Text] [Related]
29. Construction of a novel cancer-associated fibroblast-related signature to predict clinical outcome and immune response in colon adenocarcinoma.
Zheng L; Zhang J; Ye Y; Shi Z; Huang Y; Zhang M; Gui Z; Li P; Qin H; Sun W; Zhang M
Aging (Albany NY); 2023 Sep; 15(18):9521-9543. PubMed ID: 37724904
[TBL] [Abstract][Full Text] [Related]
30. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
31. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer.
Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096
[TBL] [Abstract][Full Text] [Related]
32. Identification of 9 Gene Signatures by WGCNA to Predict Prognosis for Colon Adenocarcinoma.
Yang M; He H; Peng T; Lu Y; Yu J
Comput Intell Neurosci; 2022; 2022():8598046. PubMed ID: 35392038
[TBL] [Abstract][Full Text] [Related]
33. System analysis based on the ER stress-related genes identifies WFS1 as a novel therapy target for colon cancer.
Yang X; Zhang C; Yan C; Ma L; Ma J; Meng X
Aging (Albany NY); 2022 Nov; 14(22):9243-9263. PubMed ID: 36445321
[TBL] [Abstract][Full Text] [Related]
34. Investigating gene signatures associated with immunity in colon adenocarcinoma to predict the immunotherapy effectiveness using NFM and WGCNA algorithms.
Liang W; Yang X; Li X; Wang P; Zhu Z; Liu S; Xu D; Zhi X; Xue J
Aging (Albany NY); 2024 May; 16(9):7596-7621. PubMed ID: 38742936
[TBL] [Abstract][Full Text] [Related]
35. Identification of hub genes and construction of transcriptional regulatory network for the progression of colon adenocarcinoma hub genes and TF regulatory network of colon adenocarcinoma.
Wei S; Chen J; Huang Y; Sun Q; Wang H; Liang X; Hu Z; Li X
J Cell Physiol; 2020 Mar; 235(3):2037-2048. PubMed ID: 31612481
[TBL] [Abstract][Full Text] [Related]
36. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
[TBL] [Abstract][Full Text] [Related]
37. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
Chen Y; He J; Jin T; Zhang Y; Ou Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
[TBL] [Abstract][Full Text] [Related]
38. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
[TBL] [Abstract][Full Text] [Related]
39. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
40. MiRNA-based model for predicting the TMB level in colon adenocarcinoma based on a LASSO logistic regression method.
Li Z; Jiang L; Zhao R; Huang J; Yang W; Wen Z; Zhang B; Du G
Medicine (Baltimore); 2021 May; 100(21):e26068. PubMed ID: 34032736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
